Replies to post #315494 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Exactly, you have read the study able to state succinctly what it actually says without obfuscating anything by a long essay.

[boi568]

My mental model of the S1R is a bit different than has been described.

Rather than having more or fewer receptors as we age, I think of it as differences in receptor performance as we age. In a very healthy older person, the receptors get more active to compensate for aging failures elsewhere in the cell. In others, activity is not as high but still very useful. In people with dementias, the S1 system has largely failed with age. There is a spectrum of S1 performance.

My image of 2-73 is that it agonizes and then, through its particular mechanism, stimulates necessary S1 performance. This is because the molecule is the missing element or a close cousin of the missing element in a prematurely aging receptor.

Under this construct, 2-73 would be analogous to insulin for diabetes and would need to be taken indefinitely. It would not produce a cure after a period of administration.

This is just lay speculation, and one possibility among many. I am not able to speak with authority on this subject, but it is the way I visualize the MOA and the Sigma-1 receptor system.